Novel pharmacological targets for the treatment of Parkinson's disease. - Wikidata - wikimedia - TriplyDB

Novel pharmacological targets for the treatment of Parkinson's disease.

Novel pharmacological targets for the treatment of Parkinson's disease.

http://www.wikidata.org/entity/Q36610996

about

Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via Dynamin-like protein The A(2A)-adenosine receptor: a GPCR with unique features?The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors Emerging preclinical pharmacological targets for Parkinson's disease Neuropharmacological Potential of Gastrodia elata Blume and Its Components Mechanisms and therapeutic applications of electromagnetic therapy in Parkinson's disease Advances in neuroprotective ingredients of medicinal herbs by using cellular and animal models of Parkinson's disease S-nitrosylation of Drp1 links excessive mitochondrial fission to neuronal injury in neurodegeneration Dopamine agonists in Parkinson's disease A synopsis on the role of tyrosine hydroxylase in Parkinson's disease Identification of zebrafish A2 adenosine receptors and expression in developing embryos Extracellular nucleotide and nucleoside signaling in vascular and blood disease Baicalein antagonizes rotenone-induced apoptosis in dopaminergic SH-SY5Y cells related to Parkinsonism.Xanthines as adenosine receptor antagonists.Pharmacophore mapping and in silico screening to identify new potent leads for A(2A) adenosine receptor as antagonists.Transgenic conversion of omega-6 into omega-3 fatty acids in a mouse model of Parkinson's disease.Radiosynthesis and evaluation of an 18F-labeled positron emission tomography (PET) radioligand for metabotropic glutamate receptor subtype 4 (mGlu4).Transient elevation of adult hippocampal neurogenesis after dopamine depletion.Course, prognosis, and management of psychosis in Parkinson's disease: are current treatments really effective?Solution-phase parallel synthesis and SAR of homopiperazinyl analogs as positive allosteric modulators of mGlu₄.Adenosinergic depression of glutamatergic transmission in the entorhinal cortex of juvenile rats via reduction of glutamate release probability and the number of releasable vesicles Fine-tuning serotonin2c receptor function in the brain: molecular and functional implications Nicotine and Parkinson's disease: implications for therapy.Implications of mitochondrial dynamics on neurodegeneration and on hypothalamic dysfunction.Potent Protection Against MPP(+)-Induced Neurotoxicity via Activating Transcription Factor MEF2D by a Novel Derivative of Naturally Occurring Danshensu/Tetramethylpyrazine.Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects.The cholinergic mesopontine tegmentum is a relatively neglected nicotinic master modulator of the dopaminergic system: relevance to drugs of abuse and pathology.Curcumin and neurodegenerative diseases.MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease.Death in the substantia nigra: a motor tragedy.Cell-replacement and gene-therapy strategies for Parkinson's and Alzheimer's disease.Molecular pathways and genetic aspects of Parkinson's disease: from bench to bedside.Increases in cerebrospinal fluid caffeine concentration are associated with favorable outcome after severe traumatic brain injury in humans Irregular gastrointestinal drug absorption in Parkinson's disease.Antiparkinson prodrugs.Progress in neuroprotection in Parkinson's disease.Current management of the cognitive dysfunction in Parkinson's disease: how far have we come?Iron Chelators as Potential Therapeutic Agents for Parkinson's Disease Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.

P2860

Q24336889-F14A2F39-DA59-4B7A-A1D1-CA5BBBD1685A Q24653743-74BB7252-A35F-4F20-840D-5A8523D90BB7 Q24654563-4EEB39D9-82A8-4DA9-BE59-B3003A1602FC Q24657515-6A5C4C99-21C4-4A07-8879-46B4C284C2E3 Q26764724-C14CBC70-5163-4D33-A5A8-66E18CB11D62 Q26778823-C42E0853-AC83-4D7C-B1DD-C98FA4568CFA Q26782971-CA8631BD-206A-45FF-BCB1-83BD211B7CBC Q27023467-36E79E4D-E74F-4AA9-B98C-7DBEB56089AA Q27694603-407AD706-C803-4FAD-BF8A-A7D574444C97 Q28276692-6AEF001C-2BCA-487E-A1D7-506823A7D2D3 Q28830946-B1915DD5-357F-4A0B-882F-0959BB425FF1 Q30436906-B0EC1086-F12B-4B44-AFF7-62F99372BB3A Q34047834-8F3D8B75-CA3C-4F98-AA3E-EBC2F5A71A27 Q34134659-3BCFA6A0-D54F-4750-B2D6-FA0EA7B7BDD8 Q34139398-94C5BD3C-D1F8-49DB-820E-4A34B69C68BC Q34183010-68F9F717-D3D4-4B4C-8F30-39A59C9A52D8 Q34503368-25568718-AD96-4C8C-829E-80FBD36B29FF Q34506035-E08266C5-B038-40EF-8EDA-2911B16FA74D Q34589616-94BD1C93-3EFD-4196-884F-87290450441F Q34610593-93D02940-86B9-479B-A4C6-58C6684DB6C1 Q34673489-E9FEEF21-BE89-4D60-8DBD-437559013FDD Q34685689-D1F7F8D6-0B08-4EDC-8559-1A87976561A6 Q35072763-7D448B38-DE00-4548-A307-48063ACD942E Q35601652-34D04FE3-8DD3-4123-9A22-1D504B4B59F8 Q35708874-70251CA2-50F1-4554-98CB-DCC91F4877D5 Q36045416-520A5298-06F0-4143-AB4C-1E2F3D52E858 Q36298388-A859FD81-9ADA-4223-B247-CE524D3F736B Q36497025-F08028C1-C4CD-46F5-999B-AAA74767F37E Q36625852-5B3CD5A8-2C90-4C23-A900-6736C6E8E60D Q36804513-940F5A19-4CD5-4A28-BF4D-E9F60B7573CF Q36847262-AE83D3CA-95FD-4EF3-BE64-1B8EFA13B8F8 Q36883772-A6137098-945F-4656-BFFF-E5978E11E8CF Q37021321-3031C425-1737-46FD-9AF6-8CC0C0F5C9DF Q37022293-EBDD5B8D-D834-46B2-8873-23C7E8A8C90C Q37076343-FFF50781-F9FB-4E1A-A50F-3387AAEA23C7 Q37079678-B3A56BBC-71AB-4E01-A460-13D575E68AD3 Q37114112-86BABC66-86A8-489E-9544-782D0C99E5FA Q37183932-6941C132-4E01-4991-B0E1-9031B1328A1E Q37374312-3E0DDAE8-DB8B-4209-B6A3-1DBB671BB0F0 Q37578490-E24D2C6A-C83F-41E5-A9B2-AD2F725E4B2D

P2860

Novel pharmacological targets for the treatment of Parkinson's disease.

http://www.wikidata.org/entity/Q36610996

description

2006 nî lūn-bûn

@nan

2006年の論文

@ja

2006年論文

@yue

2006年論文

@zh-hant

2006年論文

@zh-hk

2006年論文

@zh-mo

2006年論文

@zh-tw

2006年论文

@wuu

2006年论文

@zh

2006年论文

@zh-cn

name

Novel pharmacological targets for the treatment of Parkinson's disease.

@ast

Novel pharmacological targets for the treatment of Parkinson's disease.

@en

type

label

Novel pharmacological targets for the treatment of Parkinson's disease.

@ast

Novel pharmacological targets for the treatment of Parkinson's disease.

@en

prefLabel

Novel pharmacological targets for the treatment of Parkinson's disease.

@ast

Novel pharmacological targets for the treatment of Parkinson's disease.

@en

P1433

Q36610996-734A53DE-1CBC-4434-8F7D-E9899F316924

P1476

Q36610996-FF5AB711-8C0B-4C49-9505-127C770B71F6

P2093

Q36610996-016B10AA-5670-4E74-81D7-392A20378F20

Q36610996-0221A2FA-7BAA-4119-B3B8-59823BD6B975

Q36610996-3F52A640-B9EA-4C12-BFC1-9D5C7EDC2DBD

Q36610996-4CF652F1-B521-4EF1-A056-E2932F269568

Q36610996-6C3E81CB-5567-4CC8-A08E-3B4ABCEDF1CF

Q36610996-75B534ED-DED3-4551-A788-B9B0D0DCEA95

Q36610996-8DE24E3C-AEAB-4401-AEE9-079C625FA679

Q36610996-FEF9867F-E29F-4BA1-9A42-CDC05F98E955

P2860

Q36610996-06C9276B-4F68-46C2-B640-E974D4114358

Q36610996-11D8380D-490C-4043-A815-C3AE1135C798

Q36610996-7B66848F-C5D4-4E7D-B1D9-74605E2BC6A2

Q36610996-7F9995E8-63E0-4674-B7F3-EE94FE541EE7

Q36610996-A698794C-8C5D-4ED8-9EF5-C422CCD34F17

Q36610996-D6A229D9-3482-46B5-8D7F-861AFCFB3B8F

Q36610996-D6D0BA7F-6778-4929-B79A-EB81D8C4E749

Q36610996-D738AE3D-DBED-458D-94D4-497A110B6D6B

Q36610996-D7532AC3-D37E-446D-A65C-826F0C387135

Q36610996-F06FCF65-455B-4763-9DDC-EFB8FA710B91

P2888

Q36610996-6EE90D5A-2C40-457D-92BC-4886BCFE4A6C

P304

Q36610996-084AE89D-1D63-42A0-84BA-B5179B5F8F61

P31

Q36610996-85599E1C-5A0E-43A1-B3AB-478AC6A2DA73

P356

Q36610996-EF423ED1-D6FF-4BA8-9517-FD08BFDF7C3F

P433

Q36610996-67CB9425-563E-4A13-82A9-80E9190D1A84

P478

Q36610996-6240600F-B64B-4EB1-B492-61EA39F29ED0

P50

Q36610996-37C609F1-5849-4FBF-B673-0F5B8D224EFA

Q36610996-5C6DE2E0-48A0-4FDE-A267-F4926FD2BBD2

Q36610996-63EE99EA-09B3-434A-B1DA-C680E282D4DD

Q36610996-A905EEBC-DC9C-40DB-A566-9479F06FFF64

Q36610996-BE801E15-DB90-4A5D-95BD-374827D8D6DA

Q36610996-CA3CFFA5-6B9B-4F86-8D07-65CA2CCF17C5

P577

Q36610996-B71C4D2B-5039-4AC6-A0AF-6099D22157FB

P5875

Q36610996-2D501422-B7D1-42AF-9BDF-0FC6473EC665

P6179

Q36610996-95501090-99CC-4589-9030-E67F402FFF16

P698

Q36610996-BD7037E6-9F47-4E9B-96FA-3E24CCD8F7B2

P921

Q36610996-A7C7A3C6-B395-4A86-86B3-DBADDB22EB0A

P356

P1433

Nature Reviews Drug Discovery

P1476

Novel pharmacological targets for the treatment of Parkinson's disease.

@en

P2093

Bastian Hengerer

http://www.w3.org/2001/XMLSchema#string

Borris Ferger

http://www.w3.org/2001/XMLSchema#string

Etienne Hirsch

http://www.w3.org/2001/XMLSchema#string

Giora Davidai

http://www.w3.org/2001/XMLSchema#string

Graham L Collingridge

http://www.w3.org/2001/XMLSchema#string

José A Obeso

http://www.w3.org/2001/XMLSchema#string

Peter Jenner

http://www.w3.org/2001/XMLSchema#string

Umberto Spampinato

http://www.w3.org/2001/XMLSchema#string

P2860

D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys

Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models.

Adenosine A(2A) receptor antagonist treatment of Parkinson's disease.

Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease.

Caffeinated clues from epidemiology of Parkinson's disease.

Clinical studies with transdermal rotigotine in early Parkinson's disease.

Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD.

Randomized trial of the adenosine A(2A) receptor antagonist istradefylline in advanced PD.

Clozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled study.

Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias.

P2888

P304

845-854

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRD2087

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

Nicolas Le Novère

Frédéric Calon

Jonathan M. Brotchie

Anthony H V Schapira

Michael A Schwarzschild

P577

2006-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

6779541

http://www.w3.org/2001/XMLSchema#string

P6179

1020393575

http://www.w3.org/2001/XMLSchema#string

P698

17016425

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease